Overview
Publication
PLOS ONE. 2013; 8(1):e54407.
PubMed ID: 23349878
Title
Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia ankara vaccines: A systematic review
Authors
Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC for the MVA Cardiac Safety Working Group
Abstract
Vaccinia-associated myo/pericarditis was observed during the US smallpox vaccination (DryVax) campaign initiated in 2002. A highly-attenuated vaccinia strain, modified vaccinia Ankara (MVA) has been evaluated in clinical trials as a safer alternative to DryVax and as a vector for recombinant vaccines. Due to the lack of prospectively collected cardiac safety data, the US Food and Drug Administration required cardiac screening and surveillance in all clinical trials of MVA since 2004. Here, we report cardiac safety surveillance from 6 phase I trials of MVA vaccines.
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.